Cargando…

Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson’s Disease: A Single-Center, Randomized, Placebo-Controlled Trial

A six-month double-blind, placebo-controlled randomized study was conducted to ascertain whether low-dose daily niacin supplementation would improve motor symptoms in Parkinson’s disease (PD) patients. A total of 47 PD patients were assigned to receive low-dose niacin or a placebo. At the end of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wakade, Chandramohan, Chong, Raymond, Seamon, Marissa, Purohit, Sharad, Giri, Banabihari, Morgan, John C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698595/
https://www.ncbi.nlm.nih.gov/pubmed/34944695
http://dx.doi.org/10.3390/biomedicines9121881
_version_ 1784620314725974016
author Wakade, Chandramohan
Chong, Raymond
Seamon, Marissa
Purohit, Sharad
Giri, Banabihari
Morgan, John C.
author_facet Wakade, Chandramohan
Chong, Raymond
Seamon, Marissa
Purohit, Sharad
Giri, Banabihari
Morgan, John C.
author_sort Wakade, Chandramohan
collection PubMed
description A six-month double-blind, placebo-controlled randomized study was conducted to ascertain whether low-dose daily niacin supplementation would improve motor symptoms in Parkinson’s disease (PD) patients. A total of 47 PD patients were assigned to receive low-dose niacin or a placebo. At the end of the double-blind phase, all participants received open-label niacin for the next six months. All patients were evaluated at baseline, after six months, and after one year of treatment. The primary outcome measure was the Unified Parkinson’s Disease Rating Scale III (UPDRS III) scores. Secondary outcome measures were depression, sleep quality, mental flexibility and cognition, and physical fatigue. Niacin treatment was well-tolerated by forty-five subjects. The mean [95% CI] change in UPDRS III scores at six months of placebo was −0.05 [95% CI, −2.4 to 2.32], and niacin was −1.06 [95% CI, −3.68 to 1.57]. From six to twelve months when both groups received open-label niacin supplementation, the average UPDRS III scores significantly decreased for the placebo group by 4.58 [95% CI, −0.85 to 8.30] and the niacin group by 4.63 [95% CI, 1.42 to 7.83] points. Low-dose niacin supplementation is a well-tolerated adjunct therapy and may improve motor function in PD when taken over a longer period.
format Online
Article
Text
id pubmed-8698595
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86985952021-12-24 Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson’s Disease: A Single-Center, Randomized, Placebo-Controlled Trial Wakade, Chandramohan Chong, Raymond Seamon, Marissa Purohit, Sharad Giri, Banabihari Morgan, John C. Biomedicines Article A six-month double-blind, placebo-controlled randomized study was conducted to ascertain whether low-dose daily niacin supplementation would improve motor symptoms in Parkinson’s disease (PD) patients. A total of 47 PD patients were assigned to receive low-dose niacin or a placebo. At the end of the double-blind phase, all participants received open-label niacin for the next six months. All patients were evaluated at baseline, after six months, and after one year of treatment. The primary outcome measure was the Unified Parkinson’s Disease Rating Scale III (UPDRS III) scores. Secondary outcome measures were depression, sleep quality, mental flexibility and cognition, and physical fatigue. Niacin treatment was well-tolerated by forty-five subjects. The mean [95% CI] change in UPDRS III scores at six months of placebo was −0.05 [95% CI, −2.4 to 2.32], and niacin was −1.06 [95% CI, −3.68 to 1.57]. From six to twelve months when both groups received open-label niacin supplementation, the average UPDRS III scores significantly decreased for the placebo group by 4.58 [95% CI, −0.85 to 8.30] and the niacin group by 4.63 [95% CI, 1.42 to 7.83] points. Low-dose niacin supplementation is a well-tolerated adjunct therapy and may improve motor function in PD when taken over a longer period. MDPI 2021-12-10 /pmc/articles/PMC8698595/ /pubmed/34944695 http://dx.doi.org/10.3390/biomedicines9121881 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wakade, Chandramohan
Chong, Raymond
Seamon, Marissa
Purohit, Sharad
Giri, Banabihari
Morgan, John C.
Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson’s Disease: A Single-Center, Randomized, Placebo-Controlled Trial
title Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson’s Disease: A Single-Center, Randomized, Placebo-Controlled Trial
title_full Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson’s Disease: A Single-Center, Randomized, Placebo-Controlled Trial
title_fullStr Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson’s Disease: A Single-Center, Randomized, Placebo-Controlled Trial
title_full_unstemmed Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson’s Disease: A Single-Center, Randomized, Placebo-Controlled Trial
title_short Low-Dose Niacin Supplementation Improves Motor Function in US Veterans with Parkinson’s Disease: A Single-Center, Randomized, Placebo-Controlled Trial
title_sort low-dose niacin supplementation improves motor function in us veterans with parkinson’s disease: a single-center, randomized, placebo-controlled trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698595/
https://www.ncbi.nlm.nih.gov/pubmed/34944695
http://dx.doi.org/10.3390/biomedicines9121881
work_keys_str_mv AT wakadechandramohan lowdoseniacinsupplementationimprovesmotorfunctioninusveteranswithparkinsonsdiseaseasinglecenterrandomizedplacebocontrolledtrial
AT chongraymond lowdoseniacinsupplementationimprovesmotorfunctioninusveteranswithparkinsonsdiseaseasinglecenterrandomizedplacebocontrolledtrial
AT seamonmarissa lowdoseniacinsupplementationimprovesmotorfunctioninusveteranswithparkinsonsdiseaseasinglecenterrandomizedplacebocontrolledtrial
AT purohitsharad lowdoseniacinsupplementationimprovesmotorfunctioninusveteranswithparkinsonsdiseaseasinglecenterrandomizedplacebocontrolledtrial
AT giribanabihari lowdoseniacinsupplementationimprovesmotorfunctioninusveteranswithparkinsonsdiseaseasinglecenterrandomizedplacebocontrolledtrial
AT morganjohnc lowdoseniacinsupplementationimprovesmotorfunctioninusveteranswithparkinsonsdiseaseasinglecenterrandomizedplacebocontrolledtrial